Form: Sterile lyophilized powder
According to ICH Q2(R1) guidelines, the accuracy studies were performed using three levels of concentrations, i.e., 80%, 100% and 120%, by replicate analysis ( n = 3)
The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
This document includes the specific results from third-party HPLC and MS analyses, along with the batch number and manufacturing date, enabling complete lot traceability and confidence in your research materials
All of our treatment protocols are overseen by a board-certified physician as well
Pricing Framework Per-compound separate-vial sourcing at typical research-vendor pricing (May 2026): Pre-mixed blend pricing: Pattern: pre-mixed blends carry a ~5080% premium per total mg over separate-vial sourcing
